Page last updated: 2024-10-25

ciglitazone and Acquired Immunodeficiency Syndrome

ciglitazone has been researched along with Acquired Immunodeficiency Syndrome in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Skolnik, PR1
Rabbi, MF1
Mathys, JM1
Greenberg, AS1

Other Studies

1 other study available for ciglitazone and Acquired Immunodeficiency Syndrome

ArticleYear
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.
    Journal of acquired immune deficiency syndromes (1999), 2002, Sep-01, Volume: 31, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans

2002